Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

  title={Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF},
  author={Paul T.C. Wan and Mathew J. Garnett and Stephen Mark Roe and Sharlene S. W. Lee and Dan Niculescu-Duvaz and Valerie M. Good and Cancer Genome Project and C.Michael Jones and Christopher J. Marshall and Caroline J Springer and David Barford and Richard M. Marais},

Figures from this paper

Identification and Characterization of a B-Raf Kinase Alpha Helix Critical for the Activity of MEK Kinase in MAPK Signaling
The results suggest that this B-Raf alpha helix binding site on MEK could be a site to target for drug development to treat B- RafV600E-induced melanomas.
The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants
This study characterizes a special category of oncogenic kinase mutations, and elucidates the molecular basis that underlies the differential ability of RAF isoforms to stimulate MEK-ERK pathway, revealing a unique catalytic feature of RAF family kinases that can be exploited to control their activities for cancer therapies.
Impact of Feedback Phosphorylation and Raf Heterodimerization on Normal and Mutant B-Raf Signaling
ABSTRACT The B-Raf kinase is a Ras pathway effector activated by mutation in numerous human cancers and certain developmental disorders. Here we report that normal and oncogenic B-Raf proteins are
B-Raf and Raf-1 Are Regulated by Distinct Autoregulatory Mechanisms*
It is demonstrated that B-Raf activity is autoregulated, that constitutive phosphorylation of Ser445 primes B- Raf for activation, and that a key feature of phosphorylated within the activation loop or of oncogenic mutations within this region is to block autoinhibition.
The Activation of MEK1 by Enhanced Homodimerization Drives Tumorigenesis
It is demonstrated that MEK1 dimerization is required both for its activation by RAF and for its catalytic activity towards ERK, and has important implications for the design of therapies targeting hyperactive RAS/RAF/MEK/ERK signaling in cancers.
Discovery of Raf Family Is a Milestone in Deciphering the Ras-Mediated Intracellular Signaling Pathway
The physiological complexity of the regulation of Raf kinases and their connection to the ERK phosphorylation cascade is focused on and the role of Raf in tumorigenesis and the clinical application of Raf inhibitors in the treatment of cancer is discussed.
Regulation and Role of Raf-1/B-Raf Heterodimerization
The data suggest that Raf-1/B-Raf heterodimerization occurs as part of the physiological activation process and that theheterodimer has distinct biochemical properties that may be important for the regulation of some biological processes.
A dimerization-dependent mechanism drives RAF catalytic activation
It is demonstrated that RAF catalytic function is regulated in response to a specific mode of dimerization of its kinase domain, which is term the side-to-side dimer, and it is found that the RAF-related pseudo-kinase KSR also participates in forming side- to-side heterodimers with RAF and can thereby trigger RAF activation.


Activation of B‐Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601
It is reported that phosphorylation of Thr598 and Ser601, which lie between kinase subdomains VII and VIII, is essential for B‐Raf activation by Ras, and phosphorylated residues are conserved in all Raf family members from Caenorhabditis elegans to mammals.
Differential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases*
Results show that maximal activation of B-Raf merely requires signals that generate Ras-GTP, whereas activation of Raf-1 and A-Rafa requires Ras- GTP together with signals that lead to their tyrosine phosphorylation, and B-raf may be the primary target of oncogenic Ras.
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
The results suggest that the B-Raf activation segment mutations other than V599E reported in colorectal tumors do not necessarily contribute to carcinogenesis by increasing kinase and transforming activities.
Discovery of a novel Raf kinase inhibitor.
The biology of Ras signal transduction and the epidemiology of ras mutations in association with disease are discussed and the initial pre-clinical development process of the Raf kinase inhibitor BAY 43-9006 is discussed.
Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase
It is demonstrated that maturation of the tyrosine phosphorylation sites can dramatically alter the function of Raf-1 and this is the first report that a transforming Raf- 1 protein can be generated by a single amino acid substitution.
Positive and negative regulation of Raf kinase activity and function by phosphorylation
It is demonstrated that phosphorylation of C‐Raf in the kinase activation loop (residues T491 and S494) is necessary, but not sufficient, for activation, which is sufficient to confer constitutive activity upon lin‐45 Raf and induce multi‐vulva phenotypes in C.elegans.
Oligomerization activates c-Raf-1 through a Ras-dependent mechanism
Oligomerization of Raf per se promotes Raf activation through a Ras-dependent mechanism as with EGF, activation of FKBP-Raf by FK1012A is entirely Ras-GTP dependent.
Activation of the Raf-1 kinase cascade by coumermycin-induced dimerization
It is found that dimerization is by itself sufficient, in the absence of any membrane components, both to activate a modified Raf protein and to stimulate the MAP kinase cascade appropriately, indicating that homotypic oligomerization may ordinarily act to promote Raf activation in vivo.
Serine and tyrosine phosphorylations cooperate in Raf‐1, but not B‐Raf activation
There are considerable differences between the activation of the Raf proteins; Ras‐GTP mediates two phosphorylation events required for Raf‐1 activation but does not regulate such events for B‐Raf.
Requirement of Ras-GTP-Raf complexes for activation of Raf-1 by protein kinase C.
Receptor tyrosine kinase-mediated activation of the Raf-1 protein kinase is coupled to the small guanosine triphosphate (GTP)-binding protein Ras. By contrast, protein kinase C (PKC)-mediated